Prosecution Insights
Last updated: April 19, 2026

Examiner: MERCIER, MELISSA S

Tech Center 1600 • Art Units: 1615 1626

This examiner grants 72% of resolved cases

Performance Statistics

72.1%
Allow Rate
+12.1% vs TC avg
1231
Total Applications
+6.9%
Interview Lift
1012
Avg Prosecution Days
Based on 1181 resolved cases, 2023–2026

Rejection Statute Breakdown

1.1%
§101 Eligibility
17.1%
§102 Novelty
41.2%
§103 Obviousness
25.3%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18561058 PHOTOCURABLE DEVICES AND ADDITIVE MANUFACTURING METHODS OF MAKING THE SAME Non-Final OA Georgia Tech Research Corporation
18495023 DEODORANT COMPOSITIONS WITH NATURAL WAX Non-Final OA The Procter & Gamble Company
17961089 ANTIPERSPIRANT AND DEODORANT COMPOSITIONS Non-Final OA The Procter & Gamble Company
18036209 DELAYED RELEASE SOFTGEL CAPSULES Non-Final OA R.P. Scherer Technologies, LLC
18347181 COMPOSITIONS AND DEVICES INCORPORATING WATER-INSOLUBLE THERAPEUTIC AGENTS AND METHODS OF THE USE THEREOF Non-Final OA COOK MEDICAL TECHNOLOGIES LLC
18485737 PHOTOTRIGGERABLE NITRIC OXIDE-RELEASING COMPOSITIONS AND APPLICATIONS THEREOF Non-Final OA University of Georgia Research Foundation, Inc.
18275480 COMPOSITION FOR PREVENTING, ALLEVIATING OR TREATING SLEEP DISORDERS, CONTAINING, AS ACTIVE INGREDIENT, GUT MICROBIOTA OR EXTRACELLULAR VESICLES DERIVED THEREFROM Non-Final OA Kookmin University Industry Academy Cooperation Foundation
18251428 Oral Hydrogel Compositions and Uses Non-Final OA Colgate-Palmolive Company
18023274 SOL-GEL COMPOSITION Non-Final OA THE UNIVERSITY OF QUEENSLAND
18036141 TALAZOPARIB SOFT GELATIN CAPSULE DOSAGE FORM Final Rejection PFIZER INC.
18714456 FORMULATION AND METHOD FOR TOPICAL TREATMENT OF MYCOBACTERIUM ULCERANS IN BURULI ULCERS Non-Final OA MannKind Corporation
18317625 MULTI-PARTICULATE PHARMACEUTICAL COMPOSITION OF QUETIAPINE Non-Final OA Sun Pharmaceutical Industries Limited
18649055 METAL (HYDR) OXIDE COMPOSITE COMPRISING POORLY SOLUBLE DRUG, METHOD FOR MANUFACTURING SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME Final Rejection CNPHARM CO., LTD.
18624478 BIOABSORBABLE POLYMERIC COMPOSITION FOR A MEDICAL DEVICE Non-Final OA ORBUSNEICH MEDICAL PTE. LTD.
17599811 LONG-LASTING COSMETIC COMPOSITION Non-Final OA ROQUETTE FRERES
17310238 SUNSCREEN COMPOSITIONS Final Rejection BEIERSDORF AG
18005843 USE OF CANNABIDIOL IN THE TREATMENT OF SEIZURES ASSOCIATED WITH RARE EPILEPSY SYNDROMES RELATED TO GENETIC ABNORMALITIES Final Rejection Jazz Pharmaceuticals Research UK Limited
18131908 PLANT-BASED HARD CAPSULE FOR RAPID DISINTEGRATION AND METHOD THEREOF Non-Final OA HUAQIAO UNIVERSITY
18423569 PUTRESCINE TOPICAL FORMULATIONS Non-Final OA VIVIER CANADA INC.
18568694 NON-NANOPARTICULATE APPLICATION FORMS OF MACROLIDES Non-Final OA Nucleus Medical GmbH
18246582 GASTRO RETENTIVE DOSAGE FORMS COMPRISING DEUTETRABENAZINE Final Rejection AUSPEX PHARMACEUTICALS, INC.
18573294 GRIFFITHSIN FOR USE IN A METHOD OF PREVENTING OR TREATING INFECTIONS WITH RESPIRATORY VIRUSES Non-Final OA SOLMIC BIOTECH GMBH
18539830 METHODS AND COMPOSITIONS FOR SELF-REGULATED RELEASE OF ACTIVE PHARMACEUTICAL INGREDIENT Final Rejection Acura Pharmaceuticals, Inc.
18556142 Drug Delivery System for Medical Devices Non-Final OA Rontis Hellas S.A.
18286433 COMPOSITIONS Non-Final OA VITUX GROUP AS
18370572 RESCUE COMPOSITIONS FOR HYPOGLYCEMIA Non-Final OA Empire Drying Services LLC
18240284 DRUG DELIVERY SYSTEM FOR ULTRA-LOW DOSE ESTROGEN COMBINATIONS AND METHODS AND USES THEREOF Final Rejection LUPIN INC.
18264628 COMPOSITION FOR PENETRATING BLOOD-BRAIN BARRIER, CONTAINING SONOSENSITIVE LIPOSOMES AS ACTIVE INGREDIENTS Final Rejection IMGT CO, LTD.
18265987 SELF-SUSTAINED RELEASE IMMUNE ADJUVANT SUSPENSION, PREPARATION METHOD THEREFOR, AND USE THEREOF Non-Final OA INNOBM PHARMACEUTICALS CO., LTD.
17794886 TRANSDERMAL THERAPEUTIC SYSTEM COMPRISING THE INGREDIENT ROTIGOTINE AND AT LEAST ONE NON-AMINE-RESISTANT SILICONE ADHESIVE Non-Final OA Luye Pharma Switzerland AG

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month